Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01106014 · ClinicalTrials.gov registry record · Phase 3
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Phase 3 study, sponsored by Actelion.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,156
- Enrollment target
NCT01106014 is a Phase 3 study that has completed, run by Actelion. The registered enrollment target is 1,156 participants.
The verdict
NCT01106014, a Phase 3 study, has completed, sponsored by Actelion.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,156 participants
- Enrollment target
Study Summary
The AC-065A302 (GRIPHON) study is an event-driven Phase 3 study to demonstrate the effect of selexipag on time to first morbidity or mortality event in patients with pulmonary arterial hypertension.
Interventions
- DRUG Placebo
- DRUG Selexipag
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,156 participants |
| Start Date | 2009-12-01 |
| Est. Completion | 2014-10-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01106014
The ClinicalTrials.gov registry entry for NCT01106014 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,156 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actelion, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01106014 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01106014 about?
NCT01106014 is a clinical study titled "Selexipag (ACT-293987) in Pulmonary Arterial Hypertension". The AC-065A302 (GRIPHON) study is an event-driven Phase 3 study to demonstrate the effect of selexipag on time to first morbidity or mortality event in patients with pulmonary arterial hypertension.
What is the current status of trial NCT01106014?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,156 participants. The study started on 2009-12-01. Estimated completion is 2014-10-01.
What interventions are being tested in trial NCT01106014?
The interventions under investigation include: Placebo (DRUG), Selexipag (DRUG).
Who is sponsoring clinical trial NCT01106014?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.